^
Association details:
| Biomarker: | VTCN1 overexpression |
|---|---|
| Cancer: | Bladder Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer
Published date:
06/16/2022
Excerpt:
MIBC patients with the high level of B7-H4 expression (B7-H4high) were found to possess an inferior overall and recurrence-free survival. Nonetheless, substantial clinical benefits of cisplatin-based chemotherapy and anti-PD-L1 immunotherapy were observed in these patients....Despite adverse clinical outcomes, B7-H4high patients possessed superior responsiveness to chemotherapy and immunotherapy.
DOI:
10.1016/j.ejca.2022.05.022
